×

Health > Stomach cancer deaths: Countries Compared

Ian Graham, Staff Editor

Author: Ian Graham, Staff Editor

Pfizer’s experimental drug Sutent improves survival rates and reduces tumor growth in patients with a certain type of stomach cancer, according to a trial the company conducted. Results of the Pfizer study were presented at a meeting of the American Society of Clinical Oncology.

The results showed Sutent lengthened the time it took before tumors grew from 1.5 months to 6.3 months and improved survival by about 50 percent, compared to patients taking a placebo. Pfizer’s drug does have serious side effects that could limit its use. It causes fatigue so severe that patients must take a two-week break after each four-week period of treatment to recover. Sutent can cause white blood cell counts to drop, increasing patients’ vulnerability to infection, and it can also cause nausea and diarrhea.

The study is the last to be conducted before the company seeks U.S. Food and Drug Administration approval for the drug, and involved 300 patients with gastrointestinal stromal tumors whose cancer had become resistant to Gleevec, a drug manufactured by Novartis AG. About 75 percent to 80 percent of patients on Gleevec eventually become resistant to the drug.

Sutent may also be effective in treating early-stage kidney cancer, breast cancer and neuroendocrine tumors, according to preliminary results of other trials. Investigators from Memorial Sloan-Kettering Cancer Center in New York said mid-stage trials of Sutent showed that 40 percent of 169 patients with advanced cancer saw their tumors shrink.

DEFINITION: Stomach cancer deaths per 100,000 population (1995-1998).

CONTENTS

# COUNTRY AMOUNT DATE GRAPH
1 Japan 22.4 1998
2 Portugal 16 1998
3 Hungary 14.9 1998
4 Slovakia 13.2 1998
5 Poland 13 1998
6 Italy 11.5 1998
7 Czech Republic 10.2 1998
8 Spain 10 1998
9 Germany 9.3 1998
10 Austria 9.2 1998
Group of 7 countries (G7) average (profile) 9.06 1998
High income OECD countries average (profile) 8.71 1998
=11 Ireland 8.4 1998
=11 Iceland 8.4 1998
13 Finland 7.9 1998
14 Norway 7.6 1998
=15 Luxembourg 7.1 1998
=15 Greece 7.1 1998
=15 Netherlands 7.1 1998
=18 Belgium 6.9 1998
=18 United Kingdom 6.9 1998
20 New Zealand 6.2 1998
=21 Sweden 5.5 1998
=21 Denmark 5.5 1998
23 France 5.3 1998
24 Australia 5.1 1998
25 Canada 4.6 1998
26 United States 3.4 1998

Citation

"Countries Compared by Health > Stomach cancer deaths. International Statistics at NationMaster.com", World Health Organization. Aggregates compiled by NationMaster. Retrieved from http://www.nationmaster.com/country-info/stats/Health/Stomach-cancer-deaths

Health > Stomach cancer deaths: Countries Compared Map

NationMaster

Interesting observations about Health > Stomach cancer deaths

0

Pfizer’s experimental drug Sutent improves survival rates and reduces tumor growth in patients with a certain type of stomach cancer, according to a trial the company conducted. Results of the Pfizer study were presented at a meeting of the American Society of Clinical Oncology.

The results showed Sutent lengthened the time it took before tumors grew from 1.5 months to 6.3 months and improved survival by about 50 percent, compared to patients taking a placebo. Pfizer’s drug does have serious side effects that could limit its use. It causes fatigue so severe that patients must take a two-week break after each four-week period of treatment to recover. Sutent can cause white blood cell counts to drop, increasing patients’ vulnerability to infection, and it can also cause nausea and diarrhea.

The study is the last to be conducted before the company seeks U.S. Food and Drug Administration approval for the drug, and involved 300 patients with gastrointestinal stromal tumors whose cancer had become resistant to Gleevec, a drug manufactured by Novartis AG. About 75 percent to 80 percent of patients on Gleevec eventually become resistant to the drug.

Sutent may also be effective in treating early-stage kidney cancer, breast cancer and neuroendocrine tumors, according to preliminary results of other trials. Investigators from Memorial Sloan-Kettering Cancer Center in New York said mid-stage trials of Sutent showed that 40 percent of 169 patients with advanced cancer saw their tumors shrink.

Posted on 16 May 2005

Ian Graham, Staff Editor

Ian Graham, Staff Editor

Follow us on Facebook to get interesting stats: